Targeted Therapy With BRAF And MEK Inhibition For Neurological Benefit In Patients With Brain Metastases From BRAF-Mutated Melanoma.

Trial Profile

Targeted Therapy With BRAF And MEK Inhibition For Neurological Benefit In Patients With Brain Metastases From BRAF-Mutated Melanoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary) ; Vemurafenib (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 New trial record
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top